Clinical Rheumatology

, 4:278 | Cite as

Azathioprine in 50 rheumatoid arthritic patients intolerant or unresponsive to gold or penicillamine

  • E. A. Jenkins
  • B. M. Ansell
  • M. A. Hall
  • S. P. Liyanage


This is a retrospective review of 50 rheumatoid patients who had experienced side effects with gold and/or penicillamine and who were treated with azathioprine in routine clinical practice. The mean duration of the disease at commencement of azathioprine was 9.4 years; despite attempts to maintain the dose at 2.5 mg/kg.d because of minor side effects the average daily dose was 1.68 mg/kg.d. By one year, 11 (22%) had discontinued the drug due to side effects; 6 (12%) had not improved in any respect, 20 (40%) had a reduction in the total number of active joints with maintenance of function and in 13 (26%) the total number of active joints had been reduced by more than a half. During year 2 a further 4 discontinued therapy for adverse reactions. No further formal analysis has been performed though 31 patients were still on the drug with a mean duration of therapy for a period of 5 years. Ten of these had less than half their originally affected joints still active; this condition was usually associated with a fall in ESR and rise in haemoglobin but this was not invariable.

Key words

Azathioprine Rheumatoid Arthritis Intolerance to Gold/Penicillamine 


  1. 1.
    Mason, R.M., Currey, H.L.F., Barnes, C.G., Dunne, J,F., Hazleman, B.L., Strickland, I.D. Azathioprine in rheumatoid arthritis. Br Med J, 1969; i, 420–1.Google Scholar
  2. 2.
    Currey, H.L.F., Harris, J., Mason, R.M., et al. Comparison of azathioprine, cyclophosphamide and gold in treatment of rheumatoid arthritis. Br Med J, 1974, iii, 763–6.CrossRefGoogle Scholar
  3. 3.
    Dwosh, I.L., Stern, H.B., Hunter, T., Urowitz, M.B., Smythe, H.A., Ogryzlo, M.A. Azathioprine in early rheumatoid arthritis: a comparison study with gold and chloroquine. Arthritis Rheum 1977, 20, 685–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris, J., Jessop, J.D., Chaput de Saintarge, D.M. Further experience with azathioprine in rheumatoid arthritis. Br Med J, 1971, 4, 463–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Woodland, J., Chaput de Saintarge, D.M., Evans, S.J.W., Sharman, V.L., Currey, H.L.F. Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo. Ann Rheum Dis, 1981, 40, 355–359.PubMedCrossRefGoogle Scholar
  6. 6.
    Urowitz, M.B., Hunte, T., Bookman, A.A.M., Golden, D.A., Smythe H.A., Ogryzlo, M.A. Azathioprine in rheumatoid arthritis: a double-blind study comparing full to half dose. J Rheumatol, 1974, 1, 3, 274–281.Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • E. A. Jenkins
    • 1
  • B. M. Ansell
    • 2
  • M. A. Hall
    • 2
  • S. P. Liyanage
    • 3
  1. 1.Wexham Park HospitalSloughUK
  2. 2.Canadian Red Cross HospitalMaidenhead
  3. 3.Heatherwood HospitalAscotUK

Personalised recommendations